to be an important mediator of GEN-induced nephrotoxicity. The present study was designed to evaluate the efficacy of the combination of melatonin (MT) plus atorvastatin (ATO) against GEN-induced nephrotoxicity in rats. We utilized 30
male Wistar albino rats allocated in five groups each containing six rats: control, GEN (100 mg/kg/day), ATO (10 mg/kg/day) + GEN, MT (20 mg/kg/day) + GEN and ATO (10 mg/kg/day) plus MT (20 mg/kg/day) + GEN. Kidneys weight, serum creatinine and urea concentration, renal ROS, MDA, GSH levels, SOD and CAT activity were determined. GEN-induced nephrotoxicity was evidenced by marked elevations in serum urea and creatinine, kidneys weight, renal ROS and MDA levels and reduction in renal GSH level, SOD and CAT activity. MT pretreatment significantly lowered the elevated serum creatinine concentration, kidneys weight, renal ROS and MDA levels but ATO couldn't reduce these parameters but similar to MT it was able to enhance the renal GSH level, CAT and SOD activity. In D r a f t
Introduction
Gentamicin (GEN), an aminoglycoside, was first isolated from Gram-positive bacteria, Micromonospora purpurea, and it has antibiotic activity against various gram-negative microorganisms and widely applied for treatment of life-threatening gram-negative infections (Balakumar et al. 2010 ). Because of its broad-spectrum activity, rapid bactericidal action, postantibiotic effects, chemical stability, low cost and its efficacy against germs insensitive to other antibiotics, it is a first-line drug in a variety of clinical situations in spite of the introduction of newer and less toxic antibiotics against Gram-negative microorganisms (Lopez-Novoa et al. 2011; Shakil et al. 2008) . However, the risk of serious side-effects as ototoxicity and nephrotoxicity is the principal limitation of GEN therapeutic efficacy. Since kidneys play an importance role to maintain total fluid volume and acid base balance, nephrotoxicity is the major adverse effect of GEN that markedly limits its clinical use (Begg and Barclay 1995; Mathew 1992) . The specificity of GEN nephrotoxicity may be related to its re-absorption and accumulation in renal proximal convoluted tubules, reaching a concentration of 5-50 times higher than plasma level in tubular renal cells, inducing lysosomal phospholipidosis process leading to the loss of tubular renal cells brush border integrity and necrosis (AbdelRaheem et al. 2009; Balakumar et al. 2010) . GEN nephrotoxicity is a complex situation characterized by marked increased levels of serum creatinine, blood urea nitrogen (BUN) concentration, and significant decrease in glomerular filtration rate (GFR), extensive tubular epithelial cells vacuolization and desquamation, tubular fibrosis, epithelial edema, glomerular hypertrophy and severe proximal renal tubular necrosis, which eventually lead to renal failure and dysfunction (Dam et al. 2012; Romero et al. 2009; Soliman et al. 2007 ).
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Atorvastatin (ATO) belongs to statins group of cholesterol-lowering agents that effectively lowers serum cholesterol levels by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme of the mevalonate pathway, widely used in the primary and secondary cardiovascular diseases (Kapur and Musunuru 2008; Kwak et al. 2000) . In addition to antihypercholesterolemic effects, statins have other significant effects such as antiinflammatory, antioxidant, immunomodulatory (Greenwood et al. 2006; Shishehbor et al. 2003; Yoshida 2003 Pignatelli et al. 2010; Wassmann et al. 2002) .
Melatonin (MT, N-acetyl-5-methoxytryptamine) is the main secretory product of the pineal gland synthesized from tryptophan (Arendt, 1995) . It has been shown other organs such as brain, eyes, gastrointestinal tract, skin, bone marrow, immune cells, some reproductive organs, and endocrine glands are also involved in production of MT (Reiter 1991; Sehajpal et al. 2014) . MT is known to participate in many important physiological functions, including sexual behavior, sleep, immune function, and circadian rhythm (Ozler et al. 2011; Reiter et al. 2000; Reiter et al. 2005) . MT also has beneficial roles in pathophysiological processes such as management of cardiovascular complication, migraine, cluster headache and convulsion therapy (Luchetti et al. 2010) . Additionally, MT is a broadspectrum antioxidant and a free radical scavenger; not only it is able to remove reactive oxygen species (ROS) and reactive nitrogen species (RNS) by radical scavenger activity but also increases activity of antioxidant enzymes such as D r a f t superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GRd) glutathione peroxidase (GPX) and the expression of important endogenous antioxidant, glutathione (GSH) (Allegra et al. 2003; Rodriguez et al. 2004 ).
The investigation was carried out with the objective of evaluating the efficacy of MT plus ATO combination against GEN-induced nephrotoxicity in Wistar albino rats.
Materials and methods

Drugs and chemicals
Gentamicin (Sigma, USA), melatonin (Sigma, USA) and atorvastatin (Sigma, USA) were purchased from commercial sources.
Test animals
The experimental protocols used in this study were approved by the Ethics and 
Serum and tissue collection
After 8 days, the weight of animals was measured thereafter they were anesthetized by intraperitoneal injection of ketamine (30 mg/kg). Blood samples (4-6 ml) were taken by cardiac puncture after which animals were sacrificed by cervical dislocation, kidneys quickly being removed, washed with ice-cooled physiological saline and absolute and relative (organ to body weight ratio) weights of kidney were measured for all rats. Kidneys were shock-frozen in liquid nitrogen and were kept in −80°C for lipid peroxidation and ROS assay.
Serum biochemical assays
D r a f t
To obtain serum, blood samples were centrifuged at 1,500 × g for 10 min at +4°C.
Serum blood urea nitrogen (BUN) and creatinine levels were determined using an autoanalyzer (BT-TARGA-3000 model).
Estimation of lipid peroxidation
Malondialdehyde (MDA) concentrations were measured in kidney tissues as a marker of lipid peroxidation. Kidney tissues were homogenized in ice-cold tamponade containing 150 mM KCl for the determination of MDA. As previously described, MDA, referred as thiobarbituric acid reactive substance (TBARS), was determined by the absorbance of 535 nm wavelength and the results were expressed as malondialdehyde equivalents (nmol/mg protein) (Ohkawa et al. 1979 ).
Assay of superoxide dismutase activity
SOD activity was determined by using a commercially available SOD assay kit (Sigma) according to the manufacturer's instructions.
Dichlorofluorescein assay for determination of ROS levels
ROS levels in kidney were determined by using 2ʹ, 7ʹdichlorofluoresceindiacetate
(DCF-DA) fluorescence method as described (Shinomol 2007) . The fluorescence intensity of DCF was measured by a fluorescence plate reader using excitation at 485 nm and emission detection at 528 nm and results were expressed as fluorescence change percentage, where the control group was taken as 100%.
Determination of GSH level
Renal GSH level was determined according to previous method (Kuo et al. 1983) with little modifications. The method is based on the reduction of 5,5-dithiobis-2-D r a f t nitrobenzoicacid by GSH to yield a yellow component. The absorbance of this yellow component was measured at 412 nm and compared with the standard curve to determine GSH concentration.
Determination of CAT activity
CAT activity was determined by the method of Aebi (1984) using H2O2 as substrate. A decrease in absorbance due to H2O2 degradation was monitored spectrophotometrically at 240 nm for 1 min and the enzyme activity was expressed as µmol H2O2 consumed /min/mg protein.
Statistical analysis
The results were reported as mean ± S.E.M. The statistical analyses were performed using one way analysis of variance (ANOVA) by SPSS software (v.20).
Group differences were calculated by post hoc analysis using Tukey test.
Results
Treatment effects of ATO, MT and a combination of them on kidney and body weight in GEN-treated rats
No deaths or remarkable signs of external toxicity were observed in groups of animals that were given GEN, MT, ATO or a combination of MT and ATO.
Relative kidney weight significantly increased (p < 0.01) in the GEN treated group compared with control group which could be ameliorated significantly by MT and a combination of MT and ATO pretreatment (p < 0.05) whereas ATO pretreatment didn't show any effect on relative kidney weight in comparison with GEN treated group. Body weight was not affected in any animal groups (Table1).
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Effects of ATO, MT and a combination of them on serum creatinine and urea levels in GEN-treated rats
In control animals, serum creatinine and urea concentration were 0.71 ± 0.06 and 23.4 ± 1.1 mg dl −1 respectively. They significantly increased (P < 0.01 and P < 0.001, respectively) in GEN treated group. Pretreatment with MT for 7 consecutive days significantly prevented from GEN-induced increase in serum creatinine and urea levels (p < 0.05 and p < 0.01, respectively). ATO pretreatment wasn't able to prevent GEN-induced increase in serum urea and creatinine levels. In MT and ATO combination group, serum creatinine and urea concentration were 0.72 ± 0.03 and 26.4 ± 1.13 mg dl −1 respectively that were significantly lower than GEN (p < 0.01 and p < 0.001, respectively) and ATO (p < 0.05) treated groups (Table2).
Effects of ATO, MT and a combination of them on renal ROS and MDA levels in GEN-treated rats
MDA and ROS levels were elevated highly and significantly in the kidneys of GEN-intoxicated rats in comparison with control group (P < 0.001). Pretreatment of rats with MT significantly decreased renal MDA and ROS levels (p < 0.01) in comparison with GEN treated group, while ATO pretreatment wasn't able to decrease GEN-induced elevation of MDA and ROS levels. MT and ATO combination significantly decreased renal MDA and ROS levels (p < 0.001) in comparison with GEN treated and ATO pretreated groups (Figure 1-2) . 
Discussion
The clinical usefulness of GEN, a widely used aminoglycoside antibiotic for the treatment of severe gram-negative bacterial infections, is limited due to its nephrotoxicity (Shakil et al. 2008) . Results of our study confirmed that all rats injected with GEN at a dose of 100 mg/ kg (i.p.) for 8 consecutive days, presented a typical pattern of nephrotoxicity which was correlated with elevated levels of serum urea and creatinine levels that this impairment of renal function was accompanied by an increase in kidneys weight, renal ROS and MDA levels and reduction in renal GSH level, SOD and CAT activity. Our data showed the D r a f t pretreatment of rats with MT (20 mg/kg/day, p.o.) for 7 days was able to attenuate GEN-induced nephrotoxicity by preventing from GEN-induced increase in renal ROS, MDA, serum urea and creatinine levels and increasing the activity and level of antioxidative defense. Despite the improvement of antioxidant activity and level, ATO (10 mg/kg/day, p.o.) couldn't reduce renal ROS, MDA, serum urea and creatinine levels but in the presence of ATO, the beneficial effects of MT were maintained or improved.
According to experimental data, oxygen free radicals are considered to be important mediators of GEN-mediated tubular necrosis and the decrease in glomerular filtration rate. Some investigators showed that GEN enhances the generation of reactive oxygen and nitrogen species by releasing iron from renal cortical mitochondria and forming iron-GEN complexes through iron chelation, which is a potent catalyst of free-radical formation and ROS generation (BALIGA et al. 1999; Priuska and Schacht 1995; Yanagida et al. 2004) . It has been shown that GEN enhances the production of O2, H2O2 and hydroxyl radicals that can cause changes in some macromolecules via several mechanisms including membrane lipids peroxidation, nitrotyrosine formation, protein oxidation and DNA damage (Cuzzocrea et al. 2002; Fauconneau et al. 1995) . Increased production of ROS is supported by elevation of serum urea and creatinine levels, MDA level, an index of LPO, depletion of kidney reduced GSH content and decrease in antioxidant enzymes activity which could aggravate the oxidative damage (Vijayalekshmy et al. 1992; Yazar et al. 2003) .
The results of our study showed that pretreatment with MT, induced a significant decrease in kidneys weight, serum urea and creatinine levels and efficiently improved the GEN-induced elevation of ROS and MDA levels and suppression of Martin et al. 2000; Reiter et al. 2003) . MT has been shown to ameliorate early glomerulopathy mediated by oxidative stress in diabetic rats' kidneys (Ha et al. 1999) . MT has been found to be protective against renal oxidative damage induced by aluminium, adriamycin, lead, ochratoxin and Mechlorethamine (Kunak et al. 2012; Mahieu et al. 2009; Martínez-Alfaro et al. 2013; Meki and Hussein 2001; Montilla et al. 1997; Ramirez-Garcia et al. 2015) . It has been shown that MT is able to reduce renal failure mediated by glycerol, spinal cord and thermal injury. 
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Conclusions
From the results of the present study, it could be inferred that the pretreatment of rats with MT and ATO inhibits GEN-induced nephrotoxicity and it seems that MT can enhance the beneficial effects of ATO against GEN-induced nephrotoxicity.
Administration of MT plus ATO prior to GEN exposure resulted in a marked decline in kidneys weight, serum urea and creatinine concentration, renal ROS and MDA levels and also significant elevation in renal GSH level, SOD and CAT activity. These results suggest the protective effect of ATO and MT may be caused by their antioxidant properties.
Conflict of interest
There is no conflict of interest to declare. Table 1 . Effects of MT and ATO on GEN-induced alterations in the Body weight changes and kidney weights (The data were expressed as mean ± S.E.M., n = 6).
References
The data analyzed by one-way analysis of variance (ANOVA) followed by tukey test. * p<0.05, ** p<0.01 compared to the control group. # p<0.05 compared to the GEN group. Table 2 . Effects of MT and ATO on GEN-induced alterations in the serum biochemical parameters (The data were expressed as mean ± S.E.M., n = 6).
Group
Creatinine ( 1 . Levels of lipid peroxidation in the kidneys of control and experimental animals (The data were expressed as mean ± S.E.M., n = 6). Fig. 2 . Levels of ROS (% of control) in the kidneys of control and experimental animals (The data were expressed as mean ± S.E.M., n = 6). Fig. 3 . Levels of SOD in the kidneys of control and experimental animals (The data were expressed as mean ± S.E.M., n = 6). Fig. 4 . Levels of Catalase in the kidneys of control and experimental animals (The data were expressed as mean ± S.E.M., n = 6). 5 . Levels of GSH in the kidneys of control and experimental animals (The data were expressed as mean ± S.E.M., n = 6). 
